Kevin Clark is a proven leader with extensive experience scaling diagnostics companies from inception to lucrative exit on a global scale. He has successfully ushered 126 products through the FDA approval process. His career includes the development of a diagnostics company, serving as COO and CEO. He sourced investors and sold that company to one of the largest life sciences companies in the world. He took the company public, managed multinational operations and brokered mergers and acquisitions, all while developing, manufacturing and selling products that required FDA approval.
As CEO of ERBA Diagnostics, Clark brought the company to profitability following losses in nine consecutive quarters. Among his accomplishments was the sale of controlling interest of IVAX Diagnostics (now known as ERBA Diagnostics) to TransAsia Bio-Medicals, the largest diagnostics company in India. He consummated private investment of public equity (PIPE) of $30 million in common stock and warrants to grow ERBA Diagnostics through mergers and acquisitions. He managed facilities across the U.S. and internationally in England, the Czech Republic, Italy, Russia, Brazil, and France.
Prior to that he served six years as COO of IVAX Diagnostics, the parent company of ImmunoVision, Inc., which he founded in 1987 and sold to IVAX Corporation in 1995.
During his 18 years at ImmunoVision/IVAX Diagnostics, he was directly responsible for the successful development and clinical trials of 18 diagnostic test kits.
He was Executive VP and Founding Member of the Arkansas Biotechnology Association and has served on the Board for the University of Arkansas Technology Development Foundation and Arkansas BioVentures.